8-K: Disc Medicine Reports Q4/FY25, Advances Pipeline

Disc Medicine announced its Q4 and full-year 2025 financial results, highlighted by pipeline progress and a strong cash position, despite a Complete Response Letter for bitopertin.

Summary

• Reported financial results for the fourth quarter and full year ended December 31, 2025.
• Received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) in February 2026 for bitopertin in erythropoietic protoporphyria (EPP), citing insufficient evidence of association between percent change in PPIX and sunlight exposure-based endpoints.
• The Phase 3 APOLLO clinical trial of bitopertin in adults and adolescents with EPP is expected to complete enrollment in March 2026, with topline data anticipated in Q4 2026.
• Initial data from the Phase 2 RALLY-MF trial of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at the ASH Annual Meeting in December demonstrated positive, durable benefits on hemoglobin and transfusion burden across a broad range of patients, regardless of concomitant JAK inhibitor use.
• Initiated a Phase 2 study of DISC-0974 in patients with inflammatory bowel disease (IBD) and anemia in Q1 2026, with initial data expected in 2027.
• Progressing an ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and initiated a Phase 1b study of DISC-3405 in sickle cell disease (SCD) in Q4 2025, with initial data from both studies expected in 2H 2026.
• Ended Q4 2025 with approximately $791.2 million in cash, cash equivalents, and marketable securities, providing an operational runway into 2029.
• Research and Development (R&D) expenses for the full year 2025 were $170.6 million, an increase from $96.7 million in 2024.
• Selling, General and Administrative (SG&A) expenses for the full year 2025 were $65.4 million, up from $33.0 million in 2024.
• Net loss for the full year 2025 was $212.2 million, compared to a net loss of $109.4 million for 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed bag. The CRL for bitopertin is a significant setback, but the company's strong cash position and promising early data from other pipeline assets (DISC-0974, DISC-3405) provide a counterbalance, suggesting continued long-term potential despite near-term regulatory hurdles.

Positives

• Strong financial position with $791.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing an operational runway into 2029.
• Positive initial data from the Phase 2 RALLY-MF trial of DISC-0974 in anemia of myelofibrosis, demonstrating meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor therapy use.
• Advancement of the DISC-0974 program with the initiation of a Phase 2 study in inflammatory bowel disease (IBD) and anemia.
• Progress in the DISC-3405 program with an ongoing Phase 2 study in polycythemia vera and the initiation of a Phase 1b study in sickle cell disease.
• The Phase 3 APOLLO study for bitopertin is expected to complete enrollment in March 2026, indicating progress towards a pivotal data readout.

Negatives

• Received a Complete Response Letter (CRL) from the FDA in February 2026 for bitopertin, indicating a setback in the regulatory pathway for a key pipeline asset due to insufficient evidence.
• Net loss significantly increased to $212.2 million for the full year 2025, compared to $109.4 million in 2024.
• Research and Development expenses rose substantially to $170.6 million in 2025 from $96.7 million in 2024, reflecting increased operational burn.
• Selling, General and Administrative expenses also increased significantly to $65.4 million in 2025 from $33.0 million in 2024, partly due to establishing infrastructure for potential commercialization.

Risks

• The adequacy of capital to support future operations and the ability to successfully initiate and complete clinical trials.
• The difficulty in predicting the time and cost of development of product candidates.
• The timing of initiation of planned preclinical studies and clinical trials.
• The timing of the availability of data from clinical trials.
• The ability to identify additional product candidates with significant commercial potential and to expand the pipeline in hematological diseases.
• The risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval.
• The content and timing of decisions made by the FDA and other regulatory authorities.

Future Outlook

Disc Medicine expects to complete enrollment for its Phase 3 APOLLO study of bitopertin in March 2026, with topline data anticipated in Q4 2026, and an FDA decision by mid-2027 following a response to the CRL. Initial data from Phase 2 studies of DISC-3405 in PV and SCD are expected in 2H 2026, and initial data from the Phase 2 study of DISC-0974 in IBD and anemia are expected in 2027. The company projects its current cash position will fund operations into 2029.

Management Comments

• "We remain confident in the bitopertin program and the Phase 3 APOLLO study. We are fully committed to working closely with the FDA to position bitopertin for approval following the completion of APOLLO at the end of the year."
• "Our broader pipeline continues to deliver meaningful momentum."
• "DISC-0974 generated powerful data in MF anemia that further reinforces its potential to transform the treatment landscape and we look forward to providing additional updates later this year."
• "We are also excited about DISC-3405 with first in-patient data in both polycythemia vera and sickle cell disease expected later this year."

Industry Context

StockSavvy.ai notes that Disc Medicine operates in the competitive and high-risk biopharmaceutical sector, specifically targeting rare hematologic diseases. The company's strategy of developing multiple therapeutic candidates across different mechanisms (heme synthesis modulation, hepcidin suppression, hepcidin induction) aims to diversify risk and address a broad spectrum of unmet needs. The CRL for bitopertin highlights the inherent regulatory challenges in drug development, while the positive early data for DISC-0974 in MF anemia positions it as a potential differentiator in a market with limited effective treatments for this specific indication.

Stakeholder Impact

• Shareholders: Potential for increased volatility due to the CRL for bitopertin, but also long-term value potential from a diversified pipeline and strong cash runway.
• Patients: Continued hope for novel treatments for serious hematologic diseases, with ongoing clinical trials for EPP, MF anemia, PV, and SCD.
• Employees: Increased headcount and establishment of infrastructure suggest continued growth and stability, supported by a long cash runway.
• FDA/Regulatory Authorities: Ongoing engagement with the FDA regarding bitopertin's approval pathway and future submissions for other candidates.

Next Steps

• Complete enrollment for Phase 3 APOLLO study of bitopertin in March 2026.
• Present topline data from Phase 3 APOLLO study in Q4 2026.
• Submit a response to the FDA's CRL for bitopertin following APOLLO completion.
• Receive an FDA decision on bitopertin by mid-2027.
• Provide additional updates on DISC-0974 later in 2026.
• Present initial data from Phase 2 study of DISC-3405 in PV in 2H 2026.
• Present initial data from Phase 1b study of DISC-3405 in SCD in 2H 2026.
• Present initial data from Phase 2 study of DISC-0974 in IBD and anemia in 2027.

Key Dates

Recommendation

While the FDA's Complete Response Letter for bitopertin is a notable setback, the company maintains a robust cash position extending into 2029 and has demonstrated promising early clinical data for DISC-0974 in myelofibrosis anemia. The diversified pipeline with multiple ongoing trials in significant hematologic indications suggests long-term potential. However, the increased net loss and the regulatory hurdle for bitopertin warrant a cautious approach, leading to a 'hold' recommendation as investors await further clinical data and regulatory clarity.

Keywords

Disc Medicine, IRON, biopharmaceutical, hematologic diseases, bitopertin, erythropoietic protoporphyria, EPP, DISC-0974, myelofibrosis anemia, MF anemia, DISC-3405, polycythemia vera, PV, sickle cell disease, SCD, clinical trials, FDA, Complete Response Letter, financial results, cash runway, heme synthesis, iron homeostasis